替吉奥联合奥沙利铂治疗对中晚期胃癌患者血清胃泌素、survivin抗体表达的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (616 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin in the treatment of advanced gastric cancer and its effect on the expression of gastrin (GAS) and survivin antibodies in serum. Methods A total of 100 patients with advanced gastric cancer treated in the 4th People′s Hospital of Shenyang City from January 2015 to June 2017 were divided into observation group and control group by random envelope method, with 50 cases in each group. The control group was treated with Capecitabine combined with Oxaliplatin, and the observation group was treated with Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin. Both groups were treated for 4 cycles. After treatment, the short-term clinical efficacy was assessed, and adverse reactions and quality of life were evaluated. Blood GAS and survivin antibody levels were detected before and after treatment. Results The short-term total effective rate of treatment in the observation group was significantly higher than that in the control group(P ＜ 0.05). The total improvement rate of the quality of life in the observation group after treatment was significantly higher than that of the control group (P ＜ 0.05). GAS and survivin of patients in the two groups significantly decreased after treatment (P ＜ 0.05). The GAS and survivin antibodies in the blood of the patients were significantly lower than those in the control group (P ＜ 0.05), and the incidence of nausea, vomiting and diarrhea in the observation group was significantly lower than that of the control group (P ＜ 0.05). Conclusion The combination of Tegafur, Gimeracil and Oteracil Porassium Capsules and Oxaliplatin can effectively improve the clinical efficacy and reduce the levels of serum GAS and survivin antibody in patients with advanced gastric cancer. It is of high clinical value.

Key words： Tegafur Gimeracil and Oteracil Porassium Capsules Oxaliplatin Advanced gastric cancer Gastrin Survivin antibody

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LYU Xiujuan CHEN Xin WANG Yan

Cite this article:

LYU Xiujuan CHEN Xin WANG Yan. Effect of Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin on the expression of gastrin and survivin antibodies in serum of patients with advanced gastric cancer[J]. 中国医药导报, 2019, 16(11): 97-100.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2019/V16/I11/97

[1] Cerda-Opazo P，Valenzuela-Valderrama M，Wichmann I，et al. Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer [J]. Oncotarget，2018，9（16）：12 853-12 867.
[2] Quan X，Ding Y，Feng R，et al. Expression profile of cytokines in gastric cancer patients using proteomic antibody microarray [J]. Oncol Lett，2017，14（6）：7360-7366.
[3] 黎超.SOX方案一线化疗后替吉奥维持治疗晚期胃癌的临床观察[J].实用肿瘤杂志，2017，32（6）：520-524.
[4] Bozkaya Y，?魻zdemir NY，Sezer S，et al. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?[J]. Cancer Biomarkers，2018，22（1）：1-7.
[5] 李秋娴，朱剑霞，古裕莲，等.LncRNA GAS5对结肠癌细胞生长及化疗药物作用的影响[J].海南医学，2017，27（8）：1209-1211.
[6] Kiso M，Yoshihara M，Ito M，et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori，antibody and pepsinogen test：a multicenter study [J]. Gastric Cancer，2017，20（5）：764-771.
[7] 孙燕，周际昌.临床肿瘤内科手册[M].4版.北京：人民卫生出版社，2003.
[8] Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. [J]. J Clin Oncol，1993，11（1）：5-14.
[9] 罗宴吉，王猛，陈洁，等.RECIST 1.1与Choi标准在舒尼替尼治疗胃肠胰神经内分泌肿瘤早期疗效评估的比较[J].影像诊断与介入放射学，2017，26（2）：97-102.
[10] 皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤，2012，32（2）：142-144.
[11] Jung HS，Lee SI，Kang SH，et al. Monoclonal antibodies against autocrine motility factor suppress gastric cancer [J]. Oncol Lett，2017，13（6）：4925.
[12] Song S，Su Z，Xu H，et al. Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1 [J]. Cell Death & Disease，2017，8（2）：e2612.
[13] Tong K，Chang X，Chen W. Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway [J]. Oncol Lett，2017， 13（1）：518.
[14] Chen X，Yuan LQ，Li LJ，et al. Suppression of gastric cancer by extract from the tuber of amorphophallus konjac via induction of apoptosis and autophagy [J]. Oncol Rep，2017，38（2）：1051.
[15] 葛鲁倩，孙文洲，赵欣瑶，等.新辅助化疗联合间隔肿瘤细胞减灭术对晚期卵巢癌耐药性和生存时间的影响及耐药性影响因素分析[J].实用妇产科杂志，2017，33（1）：43-47.
[16] Fan L，Tan B，Li Y，et al. miR-218 promotes apoptosis of SW1417 human colon cancer cells by targeting c-FLIP [J]. Mol Med Rep，2018，17（2）：3115-3122.
[17] Nemtsova MV，Strelnikov VV，Tanas AS，et al. Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice [J]. Curr Genomics，2017，18（5）：408-415.
[18] Na YJ，Lee DH，Kim JL，et al. Abstract 2318：Cyclopamine sensitizes endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation in trail-resistant gastric cancer cells [J]. Cancer Res，2017， 77（13）：2318.
[19] 林勇，李荣洲，宋胜江，等.替吉奥胶囊治疗老年胃癌患者对血清sICAM-1、Survivin及肿瘤标志物水平的影响[J].中华全科医学，2017，15（6）：971-973.
[20] 吴志伟，陈凯，段卫明，等.凋亡抑制蛋白XIAP和Survivin在晚期胃癌中的表达及其与含多西紫杉醇方案化疗疗效的相关性[J].现代肿瘤医学，2015，23（6）：815-820.